Rituximab biosimilar evaluated by network meta-analysis.
作者信息
Chiumente Marco, Mengato Daniele, Messori Andrea
机构信息
Scientific Direction, Italian Society for Clinical Pharmacy and Therapeutics, Milano, Italy
Scuola di Specializzazione in Farmacia Ospedaliera, Dipartimento di Scienze del Farmaco, University of Padua, Italy.
出版信息
Haematologica. 2017 Dec;102(12):e497-e498. doi: 10.3324/haematol.2017.175042. Epub 2017 Sep 21.
Abstract
摘要
相似文献
1
Rituximab biosimilar evaluated by network meta-analysis.
Haematologica. 2017 Dec;102(12):e497-e498. doi: 10.3324/haematol.2017.175042. Epub 2017 Sep 21.
2
Launching biosimilar rituximab: an industry opinion on biosimilar uptake in Europe.
Immunotherapy. 2017 Jun;9(7):527-529. doi: 10.2217/imt-2017-0054. Epub 2017 May 19.
3
Comparative efficacy and safety of biosimilar rituximab and originator rituximab in combination with methotrexate in patients with active rheumatoid arthritis: A Bayesian network meta-analysis
.
Int J Clin Pharmacol Ther. 2019 Apr;57(4):188-196. doi: 10.5414/CP203360.
4
Comparative Efficacy and Safety of Biosimilar Rituximab and Originator Rituximab in Rheumatoid Arthritis and Non-Hodgkin's Lymphoma: A Systematic Review and Meta-analysis.
BioDrugs. 2019 Oct;33(5):469-483. doi: 10.1007/s40259-019-00376-z.
5
Biosimilar monoclonal antibodies for cancer treatment in adults.
Cochrane Database Syst Rev. 2024 Nov 28;11(11):CD013539. doi: 10.1002/14651858.CD013539.pub2.
6
The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries.
Adv Ther. 2017 May;34(5):1128-1144. doi: 10.1007/s12325-017-0522-y. Epub 2017 Apr 10.
7
Scientific rationale for extrapolation of biosimilar data across cancer indications: case study of CT-P10.
Future Oncol. 2017 May;13(15s):45-53. doi: 10.2217/fon-2017-0156.
8
Long-term outcome of diffuse large B-cell lymphoma: Impact of biosimilar rituximab and radiation.
Indian J Cancer. 2017 Apr-Jun;54(2):430-435. doi: 10.4103/ijc.IJC_241_17.
9
The impact of financial incentives promoting biosimilar products in oncology: A quasi-experimental study using administrative data.
PLoS One. 2024 Nov 14;19(11):e0312577. doi: 10.1371/journal.pone.0312577. eCollection 2024.
10
Real-world use and acceptance of biosimilar monoclonal antibodies of rituximab in oncology practice in the USA.
Future Oncol. 2021 Oct;17(30):3941-3950. doi: 10.2217/fon-2021-0618. Epub 2021 Jul 14.
引用本文的文献
1
Developing Biosimilars: Challenges and Opportunities.
Pharmaceut Med. 2025 Sep;39(5):341-352. doi: 10.1007/s40290-025-00578-7. Epub 2025 Jul 30.
2
Exposure-response analysis using time-to-event data for bevacizumab biosimilar SB8 and the reference bevacizumab.
Front Pharmacol. 2024 Jan 16;14:1288308. doi: 10.3389/fphar.2023.1288308. eCollection 2023.
本文引用的文献
1
"Total evidence" network meta-analysis as a tool for improving the assessment of biosimilars: application to etanercept in rheumatoid arthritis
.
Int J Clin Pharmacol Ther. 2017 Jun;55(6):517-520. doi: 10.5414/CP202877.
2
The high price of anticancer drugs: origins, implications, barriers, solutions.
Nat Rev Clin Oncol. 2017 Jun;14(6):381-390. doi: 10.1038/nrclinonc.2017.31. Epub 2017 Mar 14.
3
Rheumatologists' Perceptions of Biosimilar Medicines Prescription: Findings from a French Web-Based Survey.
BioDrugs. 2016 Dec;30(6):585-592. doi: 10.1007/s40259-016-0202-5.
4
Safety and efficacy of biosimilars in oncology.
Lancet Oncol. 2016 Nov;17(11):e502-e509. doi: 10.1016/S1470-2045(16)30374-6.
5
Biosimilars: A consideration of the regulations in the United States and European union.
Regul Toxicol Pharmacol. 2016 Apr;76:199-208. doi: 10.1016/j.yrtph.2015.12.013. Epub 2015 Dec 28.
6
Network meta-analysis: a norm for comparative effectiveness?
Lancet. 2015 Aug 15;386(9994):628-30. doi: 10.1016/S0140-6736(15)61478-7.
7
Biosimilar: what it is not.
Br J Clin Pharmacol. 2015 Nov;80(5):949-56. doi: 10.1111/bcp.12656. Epub 2015 Jun 4.
8
Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU.
Ann Hematol. 2015 Apr;94 Suppl 2(0 2):S249-57. doi: 10.1007/s00277-015-2319-x. Epub 2015 Mar 27.
9
Delivering affordable cancer care in high-income countries.
Lancet Oncol. 2011 Sep;12(10):933-80. doi: 10.1016/S1470-2045(11)70141-3.
10
A systematic review and meta-analysis of immunochemotherapy with rituximab for B-cell non-Hodgkin's lymphoma.
Acta Oncol. 2010;49(1):3-12. doi: 10.3109/02841860903150502.
Zotero 插件